MACMILLAN STEPHEN P

CEO MacMillan sells 138,358 shares ($9.3M) at $66.97 avg; holds 1.23M post-sale. Stock -19.2% from 52-week high.

Stephen P. MacMillan, Chairman, President and CEO of Hologic, executed 3 separate sales totaling 138,358 shares for $9,266,117.92 at a blended average price of $66.97 on 2025-09-22, reducing his holdings from 1,372,982 to 1,234,624 shares (-10.1%). The timing context is mixed: at the 90-day horizon, his prior trades at Hologic have been well-timed 75% of the time (3 of 4 prior sells), but the current sale occurs with the stock trading -19.2% from its 52-week high of $83.72 and only -0.9% over the 30-day window, offering limited near-term evidence of a predictive pattern. His cross-ticker track record shows 75.00% well-timed sells at the 90-day mark with an average 90-day return of +0.8%, suggesting his prior sales across all holdings have slightly missed subsequent upside. The company's P/E of 27.06 is elevated relative to its annual revenue growth of -0.0%, and this concentrated single-day disposition of approximately 10% of CEO holdings warrants investor attention to near-term company guidance and operational momentum.

CEO Macmillan sold 44,039 shares (3 transactions) at $80.60–$82.32 on 2024-07-30 for $3.6M; current price $83.20.

On 2024-07-30, Stephen P. Macmillan, Chairman, President and CEO of Hologic, executed 3 separate sales totaling 44,039 shares for $3,597,924.24, with a blended average price of $81.70. The stock currently trades at $83.20, above the transaction prices, and has appreciated 13.2% over the past 30 days and 8.7% over the past 90 days. Macmillan retains 1,157,562 shares post-transaction, representing a 3.7% reduction in holdings. His prior sell at this ticker on 2023-11-29 showed a positive 90-day return of 7.0%, indicating the stock rose after that sale rather than declining; within this limited same-ticker history, neither of his 1 prior sells was well-timed at the 90-day mark. The company faces headwinds with annual revenue declining 17.1% year-over-year despite a recent quarterly revenue of $1.0B and net income of $194.5M, trading at a P/E of 27.55. The transaction occurs after significant recent price appreciation and does not represent a reduction to minimal holdings.